Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

By
Justin.choi
-
0
33
In this single-center, Phase I trial, researchers administered anti-CD7 chimeric antigen receptor (CAR) T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with relapsed or refractory T-cell acute lymphoblastic leukemia, in single infusions at doses of 5 × 105 or 1 × 106 cells per kilogram of body weight.
[Journal of Clinical Oncology]
Pan, J., Tan, Y., Wang, G., Deng, B., Ling, Z., Song, W., Seery, S., Zhang, Y., Peng, S., Xu, J., Duan, J., Wang, Z., Yu, X., Zheng, Q., Xu, X., Yuan, Y., Yan, F., Tian, Z., Tang, K., … Feng, X. (2021). Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of Clinical Oncology, JCO.21.00389. https://doi.org/10.1200/JCO.21.00389 Cite
Abstract